Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%

MT Newswires Live

2024/11/21

Biopharmaceutical company Dimerix (ASX:DXB) confirmed that the fifth Independent Data Monitoring Committee (IDMC) review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.

The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.

The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.

Dimerix shares fell nearly 3% in afternoon trade Thursday.

Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.99%

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2485896204"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2485896204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2485896204?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485896204","market":"sh","top_or_hot":-1,"title":"Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%","media":"MT Newswires Live","content":"<html><body><p> Biopharmaceutical company Dimerix (ASX:DXB) confirmed that the fifth Independent Data Monitoring Committee (IDMC) review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.</p><p>The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.</p><p>The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.</p><p>Dimerix shares fell nearly 3% in afternoon trade Thursday.</p><p>Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.99%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDimerix Says Kidney Disease Trial to Continue After Independent Review; Shares Down 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-21 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biopharmaceutical company Dimerix (ASX:DXB) confirmed that the fifth Independent Data Monitoring Committee (IDMC) review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.</p><p>The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.</p><p>The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.</p><p>Dimerix shares fell nearly 3% in afternoon trade Thursday.</p><p>Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.99%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485896204","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485896204","pubTimestamp":1732158895,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biopharmaceutical company Dimerix  confirmed that the fifth Independent Data Monitoring Committee  review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.Dimerix shares fell nearly 3% in afternoon trade Thursday.Price : $0.33, Change: $-0.01, Percent Change: -2.99%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","DXB.AU":"DIMERIX LTD","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","BK4125":"广播","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","BK7067":"生物科技","BK7508":"医药生物股","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC"},"translate_title":"Dimerix表示肾脏疾病试验将在独立审查后继续进行；股价下跌3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"DXB.AU":0.9},"content_text":"Biopharmaceutical company Dimerix (ASX:DXB) confirmed that the fifth Independent Data Monitoring Committee (IDMC) review of the Action3 phase 3 trial data identified no safety concerns and recommended the trial's continuation, according to a Wednesday filing with the Australian bourse.The study is evaluating the efficacy and safety of the company's product candidate DMX200 in patients with focal segmental glomerulosclerosis kidney disease, the filing said.The next IDMC meeting is scheduled for the second quarter of 2025, according to the filing.Dimerix shares fell nearly 3% in afternoon trade Thursday.Price (AUD): $0.33, Change: $-0.01, Percent Change: -2.99%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}